Koirala Krishna Prasad, Sharma Vishal
Assistant Professor, Department of Ear, Nose and Throat, Manipal College of Medical Sciences , Phulbari, Pokhara, Nepal .
Associate Professor, Department of Ear, Nose and Throat, Manipal College of Medical Sciences , Phulbari, Pokhara, Nepal .
J Clin Diagn Res. 2015 Sep;9(9):MC01-3. doi: 10.7860/JCDR/2015/14893.6427. Epub 2015 Sep 1.
Thyroiditis is a disorder that involves inflammation of the thyroid gland. Subacute thyroiditis is the most common cause of acute painful thyroiditis. It is thought to be a viral inflammatory disorder. Subacute thyroiditis has been treated with either nonsteroidal anti-inflammatory drugs (NSAIDs) or high dose corticosteroids. The response to steroids is more dramatic and quicker than the NSAIDs. Prednisolone is the most commonly used corticosteroid to treat subacute thyroiditis. The usual dose is one mg/kg/day tapered over six weeks although the basis for this dose has not been established yet by prospective studies.
The current research was carried out to study if prednisolone in lower initial dose (20 mg/day tapered over four weeks) is effective in patients with acute painful thyroiditis.
This study was a prospective, cross sectional, observational study carried out at Pokhara, Nepal. All the patients presenting with anterior neck pain of less than 1 week with tender thyroid on palpation and ESR more than 30mm/h were included in the study. The patients were administered prednisolone in a starting dose of 20 mg/day tapered over four weeks. Data were collected, analysed and the results were interpreted.
One hundred and twenty two patients of acute painful thyroiditis were included in our study. Age of the patients ranged from 19 years to 69 years with the mean age of 36.58 years. Female to Male ratio was 10:1. Mean ESR was 57.03 at the time of presentation. ESR decreased to 29.63 at two weeks and 17.03 mm per hour (normal) at 4 weeks after continuation of the drug. All the patients reported with severe pain in the anterior neck at the time of presentation. Pain was completely relieved in 115 patients (94%) at 2 weeks after starting the treatment and it was better than previous in seven patients.
Twenty mg of prednisolone daily tapered over 4 weeks is an adequate treatment of subacute thyroiditis. However, dose can be drastically tapered after 2 weeks.
甲状腺炎是一种涉及甲状腺炎症的病症。亚急性甲状腺炎是急性疼痛性甲状腺炎最常见的病因。它被认为是一种病毒性炎症性疾病。亚急性甲状腺炎的治疗方法包括使用非甾体抗炎药(NSAIDs)或高剂量皮质类固醇。皮质类固醇的疗效比NSAIDs更显著、起效更快。泼尼松龙是治疗亚急性甲状腺炎最常用的皮质类固醇。常用剂量为1毫克/千克/天,在六周内逐渐减量,不过目前尚无前瞻性研究确定此剂量的依据。
开展本研究以探讨初始剂量较低(20毫克/天,在四周内逐渐减量)的泼尼松龙对急性疼痛性甲状腺炎患者是否有效。
本研究是在尼泊尔博卡拉进行的一项前瞻性、横断面观察性研究。所有出现前颈部疼痛少于1周、触诊甲状腺有压痛且血沉超过30毫米/小时的患者均纳入研究。患者接受起始剂量为20毫克/天、在四周内逐渐减量的泼尼松龙治疗。收集、分析数据并解读结果。
我们的研究纳入了122例急性疼痛性甲状腺炎患者。患者年龄在19岁至69岁之间,平均年龄为36.58岁。男女比例为10:1。就诊时平均血沉为57.03。继续用药两周后血沉降至29.63,四周后降至17.03毫米/小时(正常)。所有患者就诊时均报告前颈部剧痛。开始治疗两周后,115例患者(94%)的疼痛完全缓解,7例患者的疼痛较之前有所改善。
每日20毫克泼尼松龙在四周内逐渐减量是治疗亚急性甲状腺炎的一种充分疗法。不过,两周后剂量可大幅减量。